HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE COVER ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) CME: Take the course for this article: Screening for Prostate Cancer FREE NURSING CONTACT HOURS All Versions of this Article: caac.20026v1 59/4/264    most recent Submit a Comment to the editor Comments: View responses Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brawley, O. W. Articles by Thompson, I. M. Search for Related Content PubMed PubMed Citation Articles by Brawley, O. W. Articles by Thompson, I. M.

Screening for Prostate Cancer

¹Chief Medical Officer, American Cancer Society, Atlanta, GA
²Research Associate Professor, Departments of Urology, Epidemiology, and Biostatistics, The University of Texas Health Science Center at San Antonio, San Antonio, TX
³Professor and Chairman, Department of Urology, The University of Texas Health Science Center at San Antonio, San Antonio, TX

Corresponding author: Ian M. Thompson, MD, Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229; thompsoni{at}uthscsa.edu

To earn free CME credit or nursing contact hours for successfully completing the online quiz based on this article, go to http://CME.AmCancerSoc.org.

DISCLOSURES: Dr. Thompson serves as a consultant to Veridex. No other conflict of interest relevant to this article was reported.

In the United States, prostate cancer will affect 1 man in 6 during his lifetime. Since the mid-1980s, screening with the prostate–specific antigen (PSA) blood test has more than doubled the risk of a prostate cancer diagnosis. A decrease in prostate cancer death rates has been observed since that time, but the relative contribution of PSA testing as opposed to other factors, such as improved treatment, has been uncertain. The recent release of 2 large randomized trials suggests that if there is a benefit of screening, it is, at best, small. Methods to assess a man's risk of prostate cancer, including those tools that integrate multiple risk factors, are now available and should be used in risk assessment. Men undergoing screening for prostate cancer may reduce their risk of prostate cancer with finasteride. CA Cancer J Clin 2009;59:264-273. © 2009 American Cancer Society, Inc.

This article has been cited by other articles:

				R. M. Hoffman and S. B. Zeliadt The Cautionary Tale of PSA Testing: Comment on "Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4.0 ng/mL" Arch Intern Med, July 26, 2010; 170(14): 1262 - 1263. [Full Text] [PDF]

				M. Bigby Why the Evidence for Skin Cancer Screening Is Insufficient: Lessons From Prostate Cancer Screening Arch Dermatol, March 1, 2010; 146(3): 322 - 324. [Full Text] [PDF]

				J. Li, R. J. Coates, M. Gwinn, and M. J. Khoury Steroid 5-{alpha}-Reductase Type 2 (SRD5a2) Gene Polymorphisms and Risk of Prostate Cancer: A HuGE Review Am. J. Epidemiol., January 1, 2010; 171(1): 1 - 13. [Abstract] [Full Text] [PDF]

Comments: